 |
|
||||||
|
|
Issue Contents
October 2003 Volume 5, Issue 8 Ask the Expert: The use of DOXIL® in multiple myeloma An interview with Mohamad Hussein, M.D., Director of the Myeloma Research Program at the Cleveland Clinic Taussig Cancer Center in Cleveland, Ohio. Myeloma at the Movies Lending Library The IMF has set up a video lending library of a variety of presentations and question and answer sessions. Saluting an Incredible Human Being:<br>Dr. Robert A. Kyle Receives Lifetime Achievement Award Rochester, Minnesota is perhaps best known as the home of the Mayo Clinic. Most people to whom myeloma is not unknown also know that Rochester is home to Dr. Robert A. Kyle. The IMF Visits Italy and France Under the auspices of the IMF, IMF Scientific Advisors and distinguished Professors Mario Boccadoro and Jean-Luc Harousseau held the first ever IMF Patient & Family Seminars in their respective countries. Myeloma Patients and Oncology Nurses to Benefit from IMF/Millennium Collaboration The IMF and Millennium Pharmaceuticals have agreed to collaborate on a medical education initiative for oncology nurses nationally which will also benefit multiple myeloma patients in their care. It’s Your Attitude... It’s Your Choice Tom Bay, Ph.D. has asked audiences over and over again to answer the following questions: Whose life is it? Who’s responsible for it? What do you plan on doing about it? And last question… When? Early studies indicate targeted radioactive drug may expand treatment options for myeloma The studies involve the drug Quadramet, one of a new class of drugs that target radiation directly to bone and spare the rest of the body from exposure.
Veterans, Agent Orange, Multiple Myeloma, and VA Benefits Veterans with MM who were exposed to Agent Orange (AO) are potentially eligible for a vast array of Department of Veterans Affairs (VA) benefits. NOTE: This article was updated on July 18, 2012. |
print